- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00360594
Acamprosate Initiated During Alcohol Detoxification
10 januari 2017 uppdaterad av: Forest Laboratories
Initiating Acamprosate Within Versus Post-detoxification in the Rehabilitative Treatment of Alcohol Dependence.
Acamprosate is approved by the Food and Drug Administration (FDA) for the treatment of alcoholism.
The purpose of this study is to see if initiating acamprosate early in alcohol detoxification instead of waiting until detoxification has been completed effects the course of detoxification, adverse events during detoxification, drop out rate during the rehabilitative treatment phase, or overall efficacy of acamprosate for those with alcohol dependence who plan to receive at least two months of rehabilitative pharmacotherapy with acamprosate.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Biphasic clinical trial, consisting of a randomized, double-blind, placebo-controlled detoxification treatment phase (DP), followed by 9-week open-label rehabilitative treatment phase (RP).
Studietyp
Interventionell
Inskrivning (Faktisk)
40
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Treatment Research Center
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 70 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria for Detoxification Treatment Phase
- Males and females from the ages of 18 to 70 years old. Subjects over the age of 70 years old will be included at the discretion of the PI, with the expectation that these subjects should comprise of no more than 5% of the subjects.
- Diagnosis of current alcohol dependence according to DSM-IV criteria [DSM-IV criteria will be determined by utilizing the Mini International Neuropsychiatric Interview (MINI)].
- If necessary, can be medically detoxified in the outpatient setting, as determined by a medical clinician.
- Meets the following drinking criteria, measured by TLFB: a. reports a minimum of 48 standard alcoholic drinks (avg 12 drinks/wk) in a consecutive 30-day period over the 90-day period prior to starting pharmacotherapy, b. has 2 or more days of heavy drinking (defined as 5 or more drinks per day in males and 4 or more drinks per day in females) within 30 days of starting pharmacotherapy treatment and c. has had a drink within 48 hours of the intake/screening visit or has a CIWA score equal to or greater than 3.
- Speaks, understands and prints in English.
- Gives written informed consent.
Exclusion Criteria for Detoxification Treatment Phase (DP)
- Subjects mandated to treatment based upon a legal decision or as a condition of employment.
- Subjects with evidence of substance dependence other than alcohol or nicotine dependence.
- Subjects with psychosis or dementia at the time of the initial evaluation.
- Female Subjects who are pregnant or lactating, or female Subjects of child bearing potential who are not using acceptable methods of birth control. Acceptable methods of birth control include: tubal ligation, barrier (diaphragm or condom) with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, and oral contraceptives.
- Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits that are clinically unacceptable to the Principal Investigator. EKG first degree heart block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are allowed; liver function tests [LFTs] <5 x ULN are acceptable), Subjects with impaired renal function as indicated by corrected creatinine clearance below 80 ml/min/70 kg as determined by the modified Cockcroft equation (CDC, 1986).
- Subjects who have a positive urine drug screening (cocaine, amphetamines, opiates, barbiturates, benzodiazepines)
- Subjects who have any disease of the gastrointestinal tract, liver or kidneys that could result in a possibility of altered metabolism or excretion of the study drug. As it is not possible to enumerate the many conditions which might impair absorption, metabolism, or excretion, the investigators will be guided by evidence such as: History of major gastrointestinal tract surgery (gastrectomy, gastrostomy, bowel resection, etc.) or a history of an active peptic ulcer or chronic disease of the GI tract, (ulcerative colitis, regional enteritis, or gastrointestinal bleeding).
- Current unstable heart disease.
- Known hypersensitivity to acamprosate.
- Subjects taking psychotropic drugs (e.g., antidepressants, anxiolytic, antipsychotic, naltrexone, disulfiram, modafinil, stimulants and anticonvulsants) with the exception of oxazepam
- Subjects receiving formal psychotherapy
- Subjects having participated in any investigational drug trial within 30 days prior to the study.
- Subjects with AIDS or other serious illnesses that may require hospitalization during the study.
Inclusion Criteria for Post-Detoxification Rehabilitative Treatment Phase (RP/Phase 2) with Open-Label Acamprosate
- Has taken at least 5 days of acamprosate or placebo directly prior to initiating open-label acamprosate.
- Successfully completed, within a 14-day period, outpatient detoxification. Successful completion of detoxification is defined as having a score of 1 or lower on the Clinical Institutes Withdrawal Assessment for Alcohol (CIWA; Shaw et al., 1981), and has at least 3 consecutive days of abstinence.
- Has reduced medication taken specifically for detoxification (if applicable), i.e., oxazepam to 45 mg within 24-hour period prior to the post-detoxification rehabilitative treatment phase.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: 2
Placebo
|
3 pills (666mg) for 1998mg/day
|
Experimentell: 1
Acamprosate
|
3 pills (666 mg) for 1998mg/day
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
1) the mean number of adverse events rated moderate to severe;
Tidsram: Phase I: up to 2 weeks
|
Phase I: up to 2 weeks
|
2) the week of detoxification treatment discontinuation;
Tidsram: Phase I: up to 2 weeks
|
Phase I: up to 2 weeks
|
3) the total amount of oxazepam given;
Tidsram: Phase I: up to 2 weeks
|
Phase I: up to 2 weeks
|
4) the rate of change in CIWA scores.
Tidsram: Phase I: up to 2 weeks
|
Phase I: up to 2 weeks
|
1) the mean number of adverse events rated moderate to severe;
Tidsram: Phase II: 10 weeks
|
Phase II: 10 weeks
|
2) the week of open-label treatment discontinuation;
Tidsram: Phase II: 10 weeks
|
Phase II: 10 weeks
|
3) any reemergence of detoxification symptoms;
Tidsram: Phase II: 10 weeks
|
Phase II: 10 weeks
|
4) % pills taken over what was proposed to be prescribed (medication exposure);
Tidsram: Phase II: 10 weeks
|
Phase II: 10 weeks
|
5) % days abstinent;
Tidsram: Phase II: 10 weeks
|
Phase II: 10 weeks
|
6) % days heavy drinking.
Tidsram: Phase II: 10 weeks
|
Phase II: 10 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Changes in alcohol craving will be measured by Penn Alcohol Craving Scale (PACS; Flannery et al, 1999)
Tidsram: 12 weeks
|
12 weeks
|
Changes in anxiety symptoms will be measured by the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A; Hamilton, 1969)
Tidsram: 12 weeks
|
12 weeks
|
Changes in depressive symptoms will be measured by the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D; Hamilton 1967)
Tidsram: 12 weeks
|
12 weeks
|
Changes in social functioning will be measured by several of the subscales of the Addiction Severity Index (ASI; McLellan et al, 1992); namely, medical, legal, psychiatric, and family/social.
Tidsram: 12 weeks
|
12 weeks
|
Quality of Life, measured by the Short Form-36 Health Status Questionnaire (SF-36; Ware & Sherbourne, 1999)
Tidsram: 12 weeks
|
12 weeks
|
Overall clinical impression of improvement will be measured by the Clinical Global Impression Scale (CGI)
Tidsram: 12 weeks
|
12 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Helen Pettinati, Ph.D., University of Pennsylvania
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2006
Primärt slutförande (Faktisk)
1 september 2007
Avslutad studie (Faktisk)
1 november 2007
Studieregistreringsdatum
Först inskickad
2 augusti 2006
Först inskickad som uppfyllde QC-kriterierna
2 augusti 2006
Första postat (Uppskatta)
4 augusti 2006
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
11 januari 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 januari 2017
Senast verifierad
1 juni 2010
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 804481
- DPMC (Annan identifierare: NIDA)
- P50DA012756-07 (U.S.S. NIH-anslag/kontrakt)
- CMP-MD-08
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Alkoholmissbruk
-
University of KonstanzAfrica Mental Health FoundationAvslutad
-
University of KonstanzAfrica Mental Health FoundationAvslutadPosttraumatisk stressyndrom | Khat Use DisorderKenya